Ординатура / Офтальмология / Английские материалы / Retinoblastoma_Rodriguez-Galindo, Wilson_2010

Microscopic residual disease

–artifactual scleral invasion  106

–multivariate analysis  108

–optic nerve stump  106

–therapies  107

–trans-scleral invasion 107–108

Missense mutation  49 MLPA. See Multiplex

ligation-dependent probe amplification

Molecular genetic progression

–cell of origin  42–43

–genomic gain, post-RB1 progressive events

–genomic loss, post-RB1 progressive events

– M1 and M2 mutational events  42

– murine models

–– viral oncoprotein-induced 45–46

–RB1 gene, protein

and function  42

– senescence, transient arrest  43 Mosaicism, RB1 mutation  51 Multiplex ligation-dependent

probe amplification  49

N

Nonsense mutation  50

O

Ocular drug transporters  69 ORBIS cybersite e-consultation

site  139–140

Orbital and locoregional disease  77–78

–chemotherapy  109

–dissemination  108

–examination  109

–orbital relapse  109–110 Orthotopic xenograft model  6–7 Osteosarcoma  117–119

Subject Index

P

Periocular chemotherapy  98

–carboplatin administration

–– CCI  75

–– human-derived fibrin protein sealant  76–77

–– intravenous and subconjunctival­   75

–transscleral drug delivery

–– scleral permeability  74–75 Persistent fetal vasculature  152 Photocoagulation  95–96 Pineoblastoma  121, 122

Potential hypotheses, epidemiology

–diagnostic interval  19–20

–diet  18–19

– in vitro fertilization (IVF)  17

–nonoccupational parental exposures  18

–parental age  16–17

–parental occupations  16

–screening and media campaigns  20

–UV exposure  17–18

–viral agents  19 Preclinical models

–limitations  6

–orthotopic xenograft model 6–7

–RB1 gene  5–6

Primary primitive neuroectodermal tumor (PNET)  15, 16, 36

Primary systemic chemotherapy  91–93

Proton beam radiation therapy  57 Pseudorosettes  32, 34

R

Radiation therapy

–advantages  55–56

–extraocular and high-risk retinoblastoma  60–61

–management controversies 63–64

–nonmalignant side effects  63

–secondary malignant tumors  61–62

–treatment methods

155

– – dose–volume curves  58

–– episcleral plaque brachytherapy  58–59

–– immobilization  59–60

–– intensity-modulated radiation therapy  56–57

–– proton beam radiation therapy  57–58

Radioactive isotopes, brachyther-

RPE. See Retinal pigment epithelium

S

Second malignancy

–carboplatin ototoxicity  124

–cognitive and functional development  123–124

–cumulative incidence  115–116

–hematologic malignancies  121

– lung and epithelial cancers  120–121

–orbital growth and facial asymmetry  123

–osteosarcoma  117–119

–radiation therapy  116–117

–SIR  116–117

–skin cancers  120

–soft tissue sarcomas  119–120

–trilateral retinoblastoma  121–123

–visual outcome  123

Simian virus 40 large T-antigen (TAg)  42, 45

SIR. See Standardized incidence ratio Soft tissue sarcomas  119–120 Standardized incidence ratio (SIR)

–hematologic malignancies  121

–leiomyosarcoma  119

–radiation therapy  116–117

–risk and type, soft tissue sarcomas  119